Mapping of QLQ-C30 and QLQ-PR25 Scores to EQ-5D-5L Utility Values for Patients with Prostate Cancer Receiving Novel Androgen Receptor Signaling Inhibitors. This evidence concerns the gene AR and Familial prostate cancer.